08.03.2017 • News

Zachry Acquires Ambitech Engineering

(c) Lichtmeister/Shutterstock
(c) Lichtmeister/Shutterstock

US engineering and construction group Zachry has acquired rival firm Ambitech Engineering for an undisclosed sum. Zachry said the acquisition adds extensive resources, capabilities and market reach.

Ambitech, headquartered in Chicago, Illinois, has 750 employees in multiple locations across the US as well as in India, the Philippines and the Middle East. Its primary industry sectors include refining, petrochemicals, food and beverage, pharmaceuticals, biotechnology and consumer products.

John Zachry, chairman and CEO of Zachry, said the company is always looking for opportunities to grow and improve its capabilities. “To acquire a high-performing and well-regarded company will be a game-changer for us,” he said, adding that the Ambitech team further enhances Zachry’s ability to provide full-service support to its principal businesses across North America, including engineering, construction, maintenance, turnarounds and specialty services.

Headquartered in San Antonio, Texas, Zachry operates 35 offices with over 22,000 employees working in more than 400 locations across North America. The company has worked with major petrochemical companies such as BASF, Ineos, ExxonMobil, Chevron Phillips Chemical, among others.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read